BioLife Solutions Past Earnings Performance
Past criteria checks 0/6
BioLife Solutions's earnings have been declining at an average annual rate of -45.2%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 40.5% per year.
Key information
-45.2%
Earnings growth rate
-23.2%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 40.5% |
Return on equity | -19.7% |
Net Margin | -46.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
May 06Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
Feb 22Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
Jan 10Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Dec 10BioLife: What The Future Holds
Oct 19BioLife Solutions COO Roderick de Greef to retire
Oct 03BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Sep 27BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M
Aug 09BioLife Solutions: Sell-Side Posture Overly Optimistic, Rate Neutral
Jul 29Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Jun 15BioLife: Can This Company Successfully Turn Around?
Apr 18Temporary Setbacks At BioLife
Mar 02Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
Jan 11BioLife: Poised For Growth
Dec 22Revenue & Expenses BreakdownBeta
How BioLife Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 143 | -66 | 80 | 19 |
30 Sep 23 | 155 | -102 | 81 | 19 |
30 Jun 23 | 162 | -83 | 79 | 17 |
31 Mar 23 | 163 | -146 | 74 | 15 |
31 Dec 22 | 162 | -140 | 69 | 15 |
30 Sep 22 | 155 | -106 | 67 | 14 |
30 Jun 22 | 148 | -96 | 64 | 14 |
31 Mar 22 | 139 | -15 | 57 | 14 |
31 Dec 21 | 119 | -9 | 48 | 12 |
30 Sep 21 | 97 | 5 | 38 | 10 |
30 Jun 21 | 74 | 4 | 29 | 9 |
31 Mar 21 | 53 | -20 | 23 | 7 |
31 Dec 20 | 48 | 2 | 22 | 7 |
30 Sep 20 | 42 | 7 | 18 | 6 |
30 Jun 20 | 37 | 16 | 17 | 5 |
31 Mar 20 | 34 | 39 | 15 | 4 |
31 Dec 19 | 27 | -2 | 14 | 3 |
30 Sep 19 | 25 | -32 | 12 | 2 |
30 Jun 19 | 23 | -39 | 11 | 2 |
31 Mar 19 | 22 | -44 | 10 | 1 |
31 Dec 18 | 20 | -25 | 9 | 1 |
30 Sep 18 | 17 | 1 | 8 | 1 |
30 Jun 18 | 15 | 0 | 7 | 1 |
31 Mar 18 | 12 | -2 | 7 | 1 |
31 Dec 17 | 11 | -3 | 7 | 1 |
30 Sep 17 | 10 | -5 | 6 | 1 |
30 Jun 17 | 9 | -6 | 7 | 2 |
31 Mar 17 | 9 | -7 | 7 | 2 |
31 Dec 16 | 8 | -7 | 8 | 2 |
30 Sep 16 | 8 | -5 | 8 | 2 |
30 Jun 16 | 7 | -5 | 8 | 2 |
31 Mar 16 | 7 | -4 | 8 | 2 |
31 Dec 15 | 6 | -4 | 7 | 1 |
30 Sep 15 | 6 | -4 | 7 | 1 |
30 Jun 15 | 6 | -4 | 6 | 1 |
31 Mar 15 | 6 | -4 | 6 | 1 |
31 Dec 14 | 6 | -3 | 5 | 1 |
30 Sep 14 | 7 | -3 | 5 | 1 |
30 Jun 14 | 8 | -2 | 4 | 1 |
31 Mar 14 | 9 | -2 | 4 | 1 |
31 Dec 13 | 9 | -1 | 4 | 0 |
30 Sep 13 | 9 | -1 | 3 | 0 |
30 Jun 13 | 8 | -1 | 3 | 0 |
Quality Earnings: BLFS is currently unprofitable.
Growing Profit Margin: BLFS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLFS is unprofitable, and losses have increased over the past 5 years at a rate of 45.2% per year.
Accelerating Growth: Unable to compare BLFS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLFS is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: BLFS has a negative Return on Equity (-19.67%), as it is currently unprofitable.